CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.Licence Agreement • January 5th, 2015 • Advanced Accelerator Applications S.A. • Pharmaceutical preparations
[*] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
LICENSE AGREEMENTLicense Agreement • January 5th, 2015 • Advanced Accelerator Applications S.A. • Pharmaceutical preparations
This Agreement, executed this 12th day of June, 2007, ("the Effective Date") is made by and between [*]("[*]"), and BioSynthema Inc., a corporation organized under the laws of the State of Missouri, USA, and having its principal place of business 4041 Forest Park Blvd., S1. Louis, Missouri, 63108 USA ("BioSynthema"), and hereafter referred to as the "Agreement". For the purpose of the Agreement, BioSynthema shall include a sublicensee to the Agreement.
MAY 20, 2010 BioSynthema Inc. and Advanced Accelerator Applications, S.A. SALE AND PURCHASE AGREEMENT FOR THE ENTIRE ISSUED SHARE CAPITALOF BIOSYNTHEMA INC.Sale and Purchase Agreement • January 5th, 2015 • Advanced Accelerator Applications S.A. • Pharmaceutical preparations
The Shareholders have each agreed to transfer and sell the Company Shares owned by them and the Purchaser has agreed to purchase and pay for all the Company Shares, in each case on the terms and subject to the conditions of this Agreement.
